TABLE III.

Cox regression analysis for overall survival

Variable	Comparator	Cox regression analysis						Conditional Cox regression analysis
		Univariate analysis		p Value	Multivariate analysis		p Value	Univariate analysis		p Value	Multivariate analysis		p Value
		HR	95% CI		HR	95% CI		HR	95% CI		HR	95% CI
Pazopanib	Sunitinib	1.47	1.02 to 2.14	0.04	1.61	1.10 to 2.36	<0.01	2.31	1.36 to 3.93	<0.01	2.48	1.41 to 4.36	<0.01
ECOG PS ≥2	0–1	2.30	1.63 to 3.25	<0.01	2.05	1.43 to 2.96	<0.01	1.42	0.76 to 2.66	0.27	1.38	0.71 to 2.66	0.33
Age ≥65 years	≤65 Years	1.04	0.79 to 1.37	0.76	0.85	0.61 to 1.18	0.33	1.44	0.97 to 2.13	0.07	1.44	0.95 to 2.17	0.09
Men	Women	1.02	0.75 to 1.41	0.88	0.90	0.61 to 1.34	0.61	1.37	0.84 to 2.24	0.21	0.67	0.40 to 1.13	0.13
Synchronous	Metachronous	1.50	1.14 to 1.98	<0.01	1.50	1.10 to 2.01	<0.01	1.22	0.82 to 1.81	0.32	1.21	0.81 to 1.83	0.35
Nephrectomy (yes)a	No	0.68	0.48 to 0.97	0.03	0.97	0.66 to 1.43	0.87	0.54	0.28 to 1.03	0.06	0.91	0.42 to 1.95	0.80
Time to treatment >1 year	<1 Year	0.48	0.28 to 0.81	0.005	0.45	0.26 to 0.78	<0.01	0.67	0.34 to 1.33	0.67	0.55	0.26 to 1.16	0.12
Bone metastasis (yes)	No	1.36	1.00 to 1.86	0.05	1.43	0.99 to 2.06	0.06	1.51	0.98 to 2.34	0.06	1.55	0.92 to 2.60	0.10
Liver metastasis (yes)	No	0.84	0.50 to 1.41	0.50	0.99	0.56 to 1.75	0.98	0.88	0.43 to 1.82	0.74	1.02	0.47 to 2.23	0.96
Lung metastasis (yes)	No	0.96	0.73 to 1.26	0.76	1.11	0.80 to 1.54	0.54	0.85	0.57 to 1.25	0.41	1.03	0.65 to 1.63	0.90
Brain metastasis (yes)	No	1.52	0.80 to 2.87	0.20	2.11	1.07 to 4.14	0.03	1.07	0.34 to 3.37	0.20	1.78	0.52 to 6.10	0.36
Prior metastasectomy (yes)a	No	0.70	0.47 to 1.05	0.08	0.96	0.59 to 1.57	0.88	0.64	0.38 to 1.06	0.08	0.70	0.41 to 1.21	0.21
Metastatic locations ≤1	≥2	0.94	0.70 to 1.24	0.65	1.03	0.75 to 1.40	0.87	1.01	0.67 to 1.53	0.96	1.03	0.66 to 4.36	0.90

^aTime-dependant analysis.

HR = hazard ratio; CI = confidence interval; ECOG PS = Eastern Cooperative Oncology Group performance status.